Faye Hant to Lung Diseases, Interstitial
This is a "connection" page, showing publications Faye Hant has written about Lung Diseases, Interstitial.
Connection Strength
1.346
-
Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009 Apr; 36(4):773-80.
Score: 0.303
-
Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. Int J Rheum Dis. 2022 Feb; 25(2):163-174.
Score: 0.183
-
A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Pract Res Clin Rheumatol. 2021 09; 35(3):101707.
Score: 0.180
-
Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther. 2021 06 14; 23(1):170.
Score: 0.177
-
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. Arthritis Rheumatol. 2021 06; 73(6):1005-1013.
Score: 0.175
-
Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2020 11; 72(11):1892-1896.
Score: 0.168
-
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019 12; 71(12):2059-2067.
Score: 0.158